Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy

27 Nov 2023

Abstract excerpt

Trastuzumab has demonstrated clinical efficacy in the treatment of HER2-positive serous endometrial cancer (EC), which led to its incorporation into standard-of-care management of this aggressive disease. Acquired resistance remains an important challenge, however, and its underlying mechanisms in EC are unknown. To define the molecular changes that occur in response to anti-HER2 therapy in EC, targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38013631
DOI: 10.1002/path.6230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased HER2 expression in endometrial cancer following anti‐HER2 therapyPMID 38013631Read ↗

ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression.Semantic proximity Read ↗

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.Semantic proximity Read ↗

The Rapidly Evolving Landscape of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Endometrial Carcinoma and Other Gynecologic Malignancies.Semantic proximity Read ↗

HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.Semantic proximity Read ↗

ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.Semantic proximity Read ↗

HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.Semantic proximity Read ↗

Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assaysSemantic proximity Read ↗

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity Read ↗

HER2 Evaluation in Uterine Serous Carcinoma: Diagnostic Agreement Between Biopsy and Resection SamplesSemantic proximity Read ↗

Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma: Implications for Clinical HER2 Testing and InterpretationSemantic proximity Read ↗

HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.Semantic proximity Read ↗

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.